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Renal ischemia–reperfusion injury: 
Renal dendritic cells loudly sound 
the alarm
PJ Nelson1
Renal ischemia–reperfusion injury is a major cause of acute renal failure 
and kidney allograft dysfunction. Dong and colleagues now identify 
the surveying renal dendritic cell network as the predominant source 
of tumor necrosis factor-α during the early stages of renal ischemia–
reperfusion injury, raising the possibility for direct targeting of renal 
dendritic cells to help ameliorate this common form of renal injury and 
its sequelae.
Kidney International (2007) 71, 604–605. doi:10.1038/sj.ki.5002121
Against the physician’s credo “do no 
harm,” renal ischemia–reperfusion injury 
(IRI) stands as an anathema. As if the 
clinical burden from renal IRI second-
ary to other causes isn’t enough, kidney 
transplant care teams everywhere face 
daily the irony that at some point, the 
patient’s remedy, a kidney allograft , must 
fi rst suff er an unavoidable and trouble-
some insult: complete ischemia during 
transfer from the donor to the recipient, 
followed by reperfusion once vascular 
anastomosis in the recipient is complete. 
To counter the jeopardy this poses to 
kidney function in the recipient, inves-
tigators have worked diligently for years 
in clinical settings and in the laboratory 
to understand the pathophysiology of 
renal IRI and to devise ways to lessen its 
detriment to the allograft . Notwithstand-
ing the great strides resulting from these 
eff orts, renal IRI continues to factor into 
delayed graft  function, acute rejection, 
and chronic allograft  nephropathy.
Along the cascade of pathogenic events 
that cause renal IRI, there has been an 
appreciation for the early innate immune 
response within the kidney itself and its 
role in priming the kidney for further 
injury. One puzzling question, however, 
has been which populations of cells resi-
dent within the kidney are most important 
in mediating this ‘sterile’ infl ammatory 
response. Th anks to a study by Dong and 
colleagues1 (this issue), some answers 
are now provided. Dong et al. proceed in 
their research on renal IRI under the pre-
cept that the immediate innate immune 
responses to parenchymal injury any-
where within the kidney are orchestrated 
by resident immune cells, specifi cally renal 
dendritic cells (DCs), that are designed to 
survey for and respond to cellular dam-
age.1 Th is immunologic paradigm was 
recently buttressed by the discovery of 
the contiguous renal DC network in nor-
mal kidney.2 By carefully fractionating 
resident renal DCs from other immune 
and nonimmune renal cells aft er induc-
ing renal IRI, and by selectively ablating 
resident renal DCs with clodronate lipo-
somes before inducing renal IRI, Dong et 
al.1 demonstrate that resident renal DCs 
are the predominant source of intrarenal 
tumor necrosis factor-α (TNF-α) in early 
renal IRI (Figure 1).
Although other cytokines and chem-
okines produced by resident renal DCs 
probably play a role in the pathogen-
esis of renal IRI, the seemingly limited 
focus by Dong et al. on TNF-α1 is well 
founded. Soluble TNF-α can be abun-
dantly expressed by mononuclear phago-
cyte lineages (for example, myeloid DCs 
and macrophages), natural killer cells, 
and certain T-lymphocyte eff ectors (for 
example, T-helper 17 (Th17) and Th1 
lymphocytes) and mediates its effects 
by engaging TNF receptor-1 (TNFR-1), 
which is normally present at basal levels 
on most quiescent cells, and TNFR-2, 
which is normally present on endothelial 
cells and some leukocytes.3 Th is pleio-
tropic reservoir of TNF-α-responsive cell 
types explains TNF-α’s harmful eff ects 
when its synthesis and release are poorly 
controlled.3 During renal IRI in the allo-
graft , for example, the substantial early 
production of TNF-α by resident renal 
DCs1 and the subsequent activation of 
adjacent TNFRs could induce apoptosis of 
renal epithelium,3 and, thus, the genera-
tion of alloantigen, all the while causing 
upregulation of adhesion molecules on 
renal endothelium, thereby promoting 
extravasation of the recipient’s leukocytes 
into the allograft . Among several possi-
bilities, the latter could include preexist-
ing populations of T-lymphocyte eff ectors 
that further propagate renal IRI4 or the 
recipient’s own traffi  cking DCs, ready to 
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scavenge and present alloantigen. Indeed, 
increased levels of intrarenal TNF-α in 
early renal IRI have already been shown 
to strongly predict adverse outcomes for 
kidney allograft s.5
Th e predominant production of TNF-
α by resident renal DCs over other renal 
cells in early renal IRI1 invokes the conun-
drum of how lipopolysaccharide (LPS) 
injures the kidney. LPS, a potent inducer 
of TNF-α secretion from DCs via the pat-
tern recognition receptor (PRR) Toll-like 
receptor 4 (TLR4), can cause apoptosis of 
renal epithelium and acute renal failure 
(ARF). However, LPS can also engage 
TLR4 on other renal cell types, including 
renal epithelium.6 Th e question has been, 
then, which specific TLR4+ renal cells 
might mediate LPS-induced ARF and how 
it occurs. Th is was recently addressed by 
Cunningham and colleagues, who studied 
the renal response to LPS aft er cross-trans-
plantation of kidneys between normal 
mice and TNFR-1-null mice,7 or between 
normal mice and mice with inactive 
TLR4.8 Th ey discovered that TNFR-1-null 
kidneys placed in normal mice were pro-
tected from ARF caused by LPS, whereas 
normal kidneys placed in TNFR-1-null 
mice readily developed ARF.7 In contrast, 
kidneys with inactive TLR4 developed 
LPS-induced ARF when placed in normal 
mice, whereas normal kidneys placed in 
mice with inactive TLR4 developed mild 
ARF that eventually recovered.8 Together, 
these studies suggest that LPS does not 
directly injure renal epithelium via TLR4 
but activates other intra- and extrarenal 
TLR4+ cell populations (for example, DCs) 
to produce TNF-α and damage renal epi-
thelium via TNFR-1. Placing these studies 
on LPS-induced renal injury7,8 in the con-
text of those by Dong et al. on renal IRI,1 
one might reasonably question whether 
TNF-α is ever produced by renal cells 
other than renal DCs early aft er an insult 
at levels suffi  cient to cause autocrine- or 
paracrine-mediated injury via TNFR-1. 
Interestingly, TLR4 mediates IRI in the 
liver and in the heart.6 If the same holds 
true in the kidney, then the study by Dong 
et al.1 will be a primer for carefully explor-
ing the TLR4+ renal DC compartment 
before assigning mechanisms of injury to 
other TLR4+ renal-cell compartments.
With resident renal DCs now identifi ed 
as major infl ammatory mediators in early 
renal IRI,1 the possibility arises for direct 
targeting of renal DCs to help ameliorate 
renal IRI, particularly in allografts that 
could undergo pharmacologic precon-
ditioning. For example, if resident renal 
DCs are stimulated to produce TNF-α 
by endogenous agonists of PRRs and not 
by some other intrinsic mechanism dur-
ing renal IRI, then defi ning the repertoire 
of responsible PRRs would allow for the 
selection of appropriate PRR antagonists 
to block or attenuate the activation of 
renal DCs.6 Alternatively, signal trans-
duction pathways downstream of PRRs 
could be targeted. One recent study dem-
onstrated the potency of GSK-3 inhibition 
in modulating the downstream signaling 
from PRRs in DCs in vivo, where proin-
fl ammatory responses were switched into 
tolerogenic, anti-infl ammatory responses 
(for example, secretion of interleukin-10) 
and mice were rendered completely resist-
ant to the harmful eff ects of LPS.9 Th is is 
intriguing because development of phar-
macologic GSK-3 inhibitors is well under 
way for other renal diseases,10 making 
them potentially attractive drugs for use in 
renal IRI as well. In summary, the survey-
ing renal DC network is loudly sounding 
the alarm in renal IRI, and eff orts to target 
the renal DC compartment in the kidney 
may help to combat this common form of 
renal injury.
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Figure 1|  Renal DCs sound the alram in renal IRI. TNF-α is abundantly expressed by renal DCs 
but not by other renal cells in early renal IRI.
